SCHEMBL4873349

SCHEMBL4873349

O=[N+]([O-])c1ccc(CCl)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.45
ALDH1A1 P00352 3/20 0.45
GAA P10253 2/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
ADRA2A P08913 2/20 0.45
ADRA2B P18089 2/20 0.45
ADRA2C P18825 2/20 0.45
SLC2A1 P11166 1/20 0.45
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 4/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 2/20 0.44
CYP1A2 P05177 2/20 0.44
ALOX12 P18054 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PKM P14618 1/20 0.43
TDP1 Q9NUW8 2/20 0.43
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29394347 1.00 MAPT (0.45) MAPTALDH1A1GAARAB9ANPC1
SCHEMBL31456058 0.81 LOXL2 (0.52) MAPTALDH1A1GAARAB9ANPC1
SCHEMBL14399403 0.81 MAPT (0.45) MAPTALDH1A1GAARAB9ANPC1
SCHEMBL5380629 0.81 CYP1A2 (0.47) MAPTALDH1A1GAARAB9ANPC1
SCHEMBL15986775 0.81 MAPT (0.45) MAPTALDH1A1GAARAB9ANPC1
SCHEMBL1126175 0.81 ADRA2A (0.49) MAPTALDH1A1GAARAB9ANPC1
SCHEMBL3096453 0.81 MAPT (0.45) MAPTALDH1A1GAARAB9ANPC1
SCHEMBL28900871 0.79 ADRA2A (0.47) MAPTALDH1A1GAARAB9ANPC1
SCHEMBL8200767 0.78 POLB (0.49) MAPTALDH1A1GAARAB9ANPC1
SCHEMBL7075509 0.78 CYP2C19 (0.48) MAPTALDH1A1GAARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528781-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-01-20 US disclosed
EP-4192831-B1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2025-10-22 EP disclosed
US-20240376061-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2024-11-14 US disclosed
US-11897851-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2024-02-13 US disclosed
CN-116323599-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-06-23 CN disclosed
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-22 US disclosed
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-22 US disclosed
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-22 US disclosed
EP-4192831-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2023-06-14 EP disclosed
US-7449570-B2 Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases PTC THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
US-20060166926-A1 Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases PTC THERAPEUTICS, INC. 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR MAPT 3959/4885ALDH1A1 1044/4885GAA 1010/4885
US-11897851-B2 Heterocyclic GLP-1 agonists GLP1R, GIPR, GCGR MAPT 3959/4885ALDH1A1 1044/4885GAA 1010/4885
US-20060166926-A1 Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases NSUN2, UPF1, NSUN3 MAPT 3685/4885ALDH1A1 2951/4885GAA 131/4885
US-12528781-B2 Heterocyclic GLP-1 agonists GLP1R, GIPR, VIP MAPT 3404/4885ALDH1A1 3780/4885GAA 1396/4885
US-20240376061-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR MAPT 3959/4885ALDH1A1 1044/4885GAA 1010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.